SecBot SecBot
SECBOTREPLAY Home › Report › FATE

FATE · Fate Therapeutics announced first patient dosed in the Phase 2…

Fate Therapeutics, Inc. · PRESS-RELEASE filed Aug 14, 2026 at 07:00 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Aug 14, 2026 at 07:00 ET

Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for lupus nephritis. The trial targets ~53 patients with enrollment expected to complete by 1H2028, supported by RMAT designation and FDA CMC pilot program. This is a positive clinical milestone but no efficacy data is expected for 12-18 months.

  • First patient dosed in Phase 2 RECLAIM-LN trial (FT819) for refractory lupus nephritis
  • Trial expected to enroll ~53 patients; enrollment completion anticipated by 1H2028
  • Primary endpoint: complete renal response at Week 26
  • FT819 has RMAT designation and is in FDA CMC Development and Readiness Pilot program

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access